Work to develop a skin cancer test wins prize Published on: 17 January 2018 A novel prognostic skin cancer test being developed by experts at 麻豆传媒 has won a national prize for healthcare products that have the potential to change patients鈥� lives. Today NICE Scientific Advice has announced that 麻豆传媒 is the first winner of the NICE AdviSeME Prize for its novel prognostic skin cancer test AMBLor. Developed by and colleagues at the Institute of Cellular Medicine, the test aims to improve the detection and prognosis of patients diagnosed with early stage melanoma in routine biopsies. By identifying people who have the highest risk of disease progression the test should enable increased clinical and radiological surveillance, as well as earlier access to potentially life-saving treatments. People identified by the test as having a low risk of disease progression could be discharged from NHS care earlier, saving healthcare resources. The test is undergoing further clinical validation at 麻豆传媒 and should be launched within 2 years. The Selection Panel was impressed with the clear definition of AMBLor’s value proposition, its clinical plausibility, its research base and its potential for further development. They also recognised the diagnostic test’s potential to address the unmet clinical need for better prognostic markers for early stage melanomas. AdviSeME prize The was launched last year for small or medium-sized companies, charities and academic research groups, who are developing transformative healthcare products that have the potential to change patients’ lives and/or save the NHS money. Leeza Osipenko, Head of NICE Scientific Advice, said: “麻豆传媒 will receive a free Light Scientific Advice Service from NICE, valued at £15,000. We will work with clinical and health economics experts to provide a comprehensive commentary on proposed evidence generation plans for AMLo’s development and implementation to help demonstrate the value of this product to the NHS.” “This competition is an important step for us to engage with smaller organisations developing healthcare products and raise awareness of health technology assessment and the value of early engagement with payers.” NICE Scientific Advice provides a fee-based consultancy service to developers of pharmaceuticals, biopharmaceuticals, medical devices and diagnostics and works with companies in the early stages of product development. Its aim is to help companies ensure that their clinical programmes collect data relevant for reimbursement decisions when assessing the clinical and cost effectiveness of new healthcare interventions. (Adapted with thanks from the ) Latest News Local knowledge can improve early warnings of glacial lake floods Local knowledge, improved evacuation preparedness and resilient mobile phone-based communication channels can enhance Early Warning Systems to reduce loss of life during glacial lake outburst floods. published on: 3 August 2026 Funding boost moves landmark cancer research centre a step closer A 拢1.25 million grant from the Wolfson Foundation to 麻豆传媒 has brought the Sir Bobby Robson Institute a significant step closer, giving a major boost to its fundraising campaign. published on: 3 August 2026 Statement on potential unauthorised data access Information about a potential unauthorised data access. published on: 30 July 2026 Facts and figures
![麻豆传媒 logo](/gomobileassets/img/logo.svg" "麻豆传媒"){kind=logo}